CastleVax is devoted to the commercial development of the Newcastle disease virus (NDV) vaccine platform technology originally developed in the laboratories of Peter Palese, PhD; Adolfo GarcĂ­a-Sastre, PhD; and Florian Krammer, PhD, at the Icahn School of Medicine at Mount Sinai.

By efficiently engineering NDV to express stabilized antigenic proteins native to infectious viruses, CastleVax is developing vaccines against current and potential future pandemic threats, as well as diseases of profound unmet medical need. NDV is a member of the avian paramyxovirus family (APMV) and is well tolerated in humans.